Journal: Oncology reports

Article Title: Baicalein inhibits TNF-?-induced NF-?B activation and expression of NF-?B-regulated target gene products.

PMID/MRN: 27667548

Publication Date: 2016-Nov-26

Abstract:

The nuclear factor-?B (NF-?B) transcription factors control many physiological processes including inflammation, immunity, apoptosis and angiogenesis. In our search for NF-?B inhibitors from natural resources, we identified baicalein from Scutellaria baicalensis as an inhibitor of NF-?B activation. As examined by the NF-?B luciferase reporter assay, we found that baicalein suppressed TNF-?-induced NF-?B activation in a dose-dependent manner. It also inhibited TNF-?-induced nuclear translocation of p65 through inhibition of phosphorylation and degradation of I?B?. Furthermore, baicalein blocked the TNF-?-induced expression of NF-?B target genes involved in anti-apoptosis (cIAP-1, cIAP-2, FLIP and BCL-2), proliferation (COX-2, cyclinĘD1 and c-Myc), invasion (MMP-9), angiogenesis (VEGF) and major inflammatory cytokines (IL-8 and MCP1). The flow cytometric analysis indicated that baicalein potentiated TNF-?-induced apoptosis and induced G1 phase arrest in HeLa cells. Moreover, baicalein significantly blocked activation of p38, extracellular signal-regulated kinase 1/2 (ERK1/2). Our results imply that baicalein could be a lead compound for the modulation of inflammatory diseases as well as certain cancers in which inhibition of NF-?B activity may be desirable.